ZA963287B - Modified anti-icam-1 antibodies and their use in the treatment of inflammation - Google Patents
Modified anti-icam-1 antibodies and their use in the treatment of inflammationInfo
- Publication number
- ZA963287B ZA963287B ZA963287A ZA963287A ZA963287B ZA 963287 B ZA963287 B ZA 963287B ZA 963287 A ZA963287 A ZA 963287A ZA 963287 A ZA963287 A ZA 963287A ZA 963287 B ZA963287 B ZA 963287B
- Authority
- ZA
- South Africa
- Prior art keywords
- icam
- inflammation
- antibodies
- treatment
- modified anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/427,355 US5695760A (en) | 1995-04-24 | 1995-04-24 | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA963287B true ZA963287B (en) | 1996-08-13 |
Family
ID=23694512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA963287A ZA963287B (en) | 1995-04-24 | 1996-04-24 | Modified anti-icam-1 antibodies and their use in the treatment of inflammation |
Country Status (12)
Country | Link |
---|---|
US (1) | US5695760A (fr) |
EP (1) | EP0822942A1 (fr) |
JP (1) | JPH11504516A (fr) |
AR (1) | AR001811A1 (fr) |
AU (1) | AU5563396A (fr) |
CO (1) | CO4700485A1 (fr) |
IL (1) | IL117993A (fr) |
MY (1) | MY113490A (fr) |
PE (1) | PE13297A1 (fr) |
TW (1) | TW438809B (fr) |
WO (1) | WO1996034015A1 (fr) |
ZA (1) | ZA963287B (fr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6130202A (en) * | 1990-07-20 | 2000-10-10 | Bayer Corporation | Antiviral methods |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
ATE265863T1 (de) * | 1995-06-07 | 2004-05-15 | Imarx Pharmaceutical Corp | Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung |
US20040121415A1 (en) * | 1996-12-10 | 2004-06-24 | King David John | Monovalent antibody fragments |
ATE342729T1 (de) * | 1997-01-15 | 2006-11-15 | Phoenix Pharmacologics Inc | Modifizierter tumor-nekrosefaktor |
US7122636B1 (en) * | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
DE69821338T2 (de) | 1997-02-21 | 2004-10-21 | Genentech Inc | Antikörperfragment-polymerkonjugate |
US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
US7005504B2 (en) * | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
PL192364B1 (pl) * | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
JP2001066308A (ja) * | 1999-07-29 | 2001-03-16 | Gsf Forschungszentrum Fuer Umwelt & Gesundheit Gmbh | IgG抗体の不可逆的損傷の検出 |
CA2402417A1 (fr) * | 2000-03-02 | 2001-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Procede de separation et de purification de proteine |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
CA2424977C (fr) * | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Procede de purification d'un anticorps |
US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
BR0207399A (pt) | 2001-02-20 | 2004-10-26 | Ortho Mcneil Pharm Inc | Método de terapia com células para o tratamento de tumores |
US6787635B2 (en) * | 2001-04-05 | 2004-09-07 | 3M Innovative Properties Company | Solid phase synthesis supports and methods |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
WO2003103475A2 (fr) | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention et reduction de la perte sanguine |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
AU2003294318A1 (en) * | 2002-11-15 | 2004-06-15 | Arizona Board Of Regents Arizona State University | Therapeutic bioconjugates |
AU2003282883B2 (en) | 2002-11-18 | 2008-12-04 | Polaris Group | Methods for inhibiting viral replication in vivo |
MXPA05010773A (es) | 2003-04-09 | 2005-12-12 | Neose Technologies Inc | Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos. |
CA2523912A1 (fr) * | 2003-04-30 | 2004-11-11 | Japan Science And Technology Agency | Anticorps humain d'interleukine-18 antihumaine, fragment de celle-ci et procede d'utilisation correspondant |
ES2538469T3 (es) | 2003-06-05 | 2015-06-22 | Genentech, Inc. | Terapia de combinación para trastornos de células B |
WO2005012484A2 (fr) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Conjugues anticorps-toxines |
WO2005021557A2 (fr) * | 2003-08-29 | 2005-03-10 | Dyax Corp. | Inhibiteurs de protease poly-pegylee |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US7686959B2 (en) * | 2004-05-05 | 2010-03-30 | Biotage Ab | Control system and method for flash separation |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
JP5948627B2 (ja) | 2004-10-29 | 2016-07-20 | レイショファーム ゲーエムベーハー | 線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化 |
EP1858543B1 (fr) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Facteur de stimulation de colonie de granulocytes glycopegylé |
EP2386571B1 (fr) | 2005-04-08 | 2016-06-01 | ratiopharm GmbH | Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase |
JP5415071B2 (ja) | 2005-08-19 | 2014-02-12 | ワイス・エルエルシー | Gdf−8に対するアンタゴニスト抗体ならびにalsおよびその他のgdf−8関連障害の処置における使用 |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
EP2267030A1 (fr) * | 2005-08-25 | 2010-12-29 | Repair Technologies, Inc. | Dispositifs, compositions et méthodes de protection et de réparation de cellules et de tissus |
WO2007056191A2 (fr) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Purification de sucre de nucleotide en utilisant des membranes |
GB0525214D0 (en) * | 2005-12-12 | 2006-01-18 | Bioinvent Int Ab | Biological materials and uses thereof |
WO2007115150A2 (fr) * | 2006-03-31 | 2007-10-11 | Centocor, Inc. | Partenaires de liaison présentant des domaines d'immunoglobuline modifiés pour avoir une demi-vie plus longue |
CA2648582C (fr) | 2006-04-07 | 2016-12-06 | Nektar Therapeutics Al, Corporation | Conjugues d'un anticorps anti-tnf-alpha |
JP5072275B2 (ja) * | 2006-07-03 | 2012-11-14 | テルモ株式会社 | 閉鎖小胞の分離方法、製剤の製造方法および評価方法 |
US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
US20080047899A1 (en) * | 2006-08-23 | 2008-02-28 | Teledyne Isco, Inc. | Gradient liquid chromatography enhancement system |
JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | ポリペプチドコンジュゲートの精製方法 |
KR20150064246A (ko) | 2007-04-03 | 2015-06-10 | 바이오제너릭스 게엠베하 | 글리코페길화 g―csf를 이용하는 치료 방법 |
CA2690611C (fr) | 2007-06-12 | 2015-12-08 | Novo Nordisk A/S | Procede ameliore pour la production de sucres de nucleotide |
WO2009026334A2 (fr) * | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Traitement par des inhibiteurs de la kallikréine |
EP2200631A1 (fr) | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Combinaison d'agents d'inhibition de blys et d'agents anti-cd 20 pour le traitement d'une maladie auto-immune |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
WO2009108806A1 (fr) | 2008-02-27 | 2009-09-03 | Novo Nordisk A/S | Molécules de facteur viii conjuguées |
US8026343B2 (en) * | 2008-08-08 | 2011-09-27 | Dinona Inc. | Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof |
CN102307594A (zh) * | 2009-01-06 | 2012-01-04 | 戴埃克斯有限公司 | 用激肽释放酶抑制剂治疗粘膜炎 |
HUE039605T2 (hu) | 2010-01-06 | 2019-01-28 | Dyax Corp | Plazma kallikreint kötõ proteinek |
KR102320178B1 (ko) | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
EP2861617A1 (fr) | 2012-06-15 | 2015-04-22 | Pfizer Inc. | Anticorps antagonistes améliorés dirigés contre gdf-8 et leurs utilisations |
EP2983711A4 (fr) | 2013-04-08 | 2016-11-23 | Cytodyn Inc | Anticorps félinisés et méthodes de traitement d'infections rétrovirales chez les félins |
WO2015148790A1 (fr) | 2014-03-27 | 2015-10-01 | Dyax Corp. | Compositions et procédés pour le traitement de l'oedème maculaire diabétique |
US10329323B2 (en) * | 2014-07-25 | 2019-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Method for purifying antibodies using PBS |
NZ744233A (en) | 2015-12-11 | 2023-11-24 | Takeda Pharmaceuticals Co | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
AU2017312785A1 (en) | 2016-08-16 | 2019-01-24 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS57203017A (en) * | 1981-06-09 | 1982-12-13 | Fujirebio Inc | Purifying method of immunoglobulin |
US4371520A (en) * | 1981-10-28 | 1983-02-01 | The Green Cross Corporation | Process for preparing immunoglobulin suitable for intravenous injection |
JPS59157017A (ja) * | 1983-02-25 | 1984-09-06 | Green Cross Corp:The | 静脈投与用γ−グロブリン製剤 |
JPS59169492A (ja) * | 1983-03-15 | 1984-09-25 | Asahi Chem Ind Co Ltd | ヒト融合細胞からの生理活性物質の産生方法 |
US4649115A (en) * | 1983-03-31 | 1987-03-10 | Sloan-Kettering Institute | Monoclonal antibodies to skin cells |
US4719290A (en) * | 1983-09-02 | 1988-01-12 | Armour Pharmaceutical Corporation | Composition of intravenous immune globulin |
GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
US4917888A (en) * | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US5308626A (en) * | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4745180A (en) * | 1986-06-27 | 1988-05-17 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using heparin fragments |
DE3641115A1 (de) * | 1986-12-02 | 1988-06-16 | Lentia Gmbh | Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins |
US5284931A (en) * | 1987-05-04 | 1994-02-08 | Dana Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
US5080891A (en) * | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5286852A (en) * | 1988-07-06 | 1994-02-15 | Verigen, Inc. | Antibodies specific towards HIV-1 gp 48 |
US5349052A (en) * | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
US5091176A (en) * | 1988-11-02 | 1992-02-25 | W. R. Grace & Co.-Conn. | Polymer-modified peptide drugs having enhanced biological and pharmacological activities |
US5304595A (en) * | 1988-11-21 | 1994-04-19 | Collagen Corporation | Collagen-polymer conjugates |
US5342940A (en) * | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
US5171663A (en) * | 1989-06-14 | 1992-12-15 | The United Stated Of America As Represented By The Secretary Of The Department Of Health And Human Services | Monoclonal antibody against regulatory protein, sgp 120 |
US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
GB9009549D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Recombinant antibody and method |
ES2115618T3 (es) * | 1990-08-31 | 1998-07-01 | Boehringer Ingelheim Pharma | Uso de anticuerpos anti-icam en la preparacion de un medicamento para el tratamiento del choque por endotoxinas. |
US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5169627A (en) * | 1991-10-28 | 1992-12-08 | Mount Sinai School Of Medicine Of The City University Of New York | Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity |
CA2131190C (fr) * | 1992-02-28 | 2008-08-12 | Peter E. Lipsky | Compositions et methodes pour traiter les blessures par brulure |
-
1995
- 1995-04-24 US US08/427,355 patent/US5695760A/en not_active Expired - Lifetime
-
1996
- 1996-04-21 IL IL11799396A patent/IL117993A/xx not_active IP Right Cessation
- 1996-04-23 WO PCT/US1996/005550 patent/WO1996034015A1/fr not_active Application Discontinuation
- 1996-04-23 MY MYPI96001543A patent/MY113490A/en unknown
- 1996-04-23 AU AU55633/96A patent/AU5563396A/en not_active Abandoned
- 1996-04-23 CO CO96019562A patent/CO4700485A1/es unknown
- 1996-04-23 JP JP8532624A patent/JPH11504516A/ja active Pending
- 1996-04-23 EP EP96912995A patent/EP0822942A1/fr not_active Withdrawn
- 1996-04-24 AR AR33626196A patent/AR001811A1/es not_active Suspension/Interruption
- 1996-04-24 PE PE1996000284A patent/PE13297A1/es not_active Application Discontinuation
- 1996-04-24 ZA ZA963287A patent/ZA963287B/xx unknown
- 1996-08-26 TW TW085110360A patent/TW438809B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PE13297A1 (es) | 1997-04-10 |
WO1996034015A1 (fr) | 1996-10-31 |
US5695760A (en) | 1997-12-09 |
IL117993A0 (en) | 1996-08-04 |
IL117993A (en) | 2000-08-31 |
MY113490A (en) | 2002-03-30 |
EP0822942A1 (fr) | 1998-02-11 |
JPH11504516A (ja) | 1999-04-27 |
TW438809B (en) | 2001-06-07 |
AR001811A1 (es) | 1997-12-10 |
AU5563396A (en) | 1996-11-18 |
CO4700485A1 (es) | 1998-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA963287B (en) | Modified anti-icam-1 antibodies and their use in the treatment of inflammation | |
AU7230196A (en) | Pskh-1 ribozymes and uses in disease treatment | |
EP0963219A4 (fr) | Manipulations de stress nitrosant et oxydatif dans le traitement d'une maladie | |
HK1015280A1 (en) | Use of epinastine in the treatment of pain | |
AU5687896A (en) | Use of alpha 1L-agonists in the treatment of incontinence | |
GR980300033T1 (en) | Compositions for the treatment of dermatological disorders and methods for their use | |
IL122215A0 (en) | Dolastatin derivatives their preparation and use | |
IL118442A0 (en) | Triazolymethyl-cyclopentanols their preparation and use | |
IL118441A0 (en) | Triazolymethyl-oxiranes their preparation and use | |
ATE225662T1 (de) | Verwendung von unverdaulichen oligosacchariden zur vorbeugung und behandlung von mittelohrentzündung bei menschen | |
GB2314273B (en) | The use of TCET in the prophylaxis and treatment of allergies | |
GB9419553D0 (en) | Polypeptides and their use in the treatment of auto-immune disease | |
IL129460A0 (en) | Use of lofexidine in the treatment of behavioral disorders | |
ZA959904B (en) | Iminooxymethyleneanilides thei preparation and their use | |
GB9514816D0 (en) | Substances and their medical use | |
DE69603226D1 (de) | Jodkomplex und dessen Verwendung | |
IL118444A0 (en) | Mercapto-triazolyl-silanes their preparation and use | |
IL122686A0 (en) | Benzylhydroxylamines their preparation and use | |
AU2705495A (en) | Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory | |
GB9416321D0 (en) | Peptides and antibodies and their use in treatment of carcinomas | |
IL109356A0 (en) | N-substituted-2-azetidinones and their use in the preparation of n-unsubstituted-2-azetidinones | |
AUPN650795A0 (en) | Encapsulated substances and their use in the treatment of animals | |
GB9523066D0 (en) | Compounds and their therapeutic use | |
AUPM932194A0 (en) | Encapsulated substances and their use in the treatment of animals | |
ZA964382B (en) | Lymphotoxin and thrombopoietin for use in the treatment of cancer. |